SCHEMBL3268358

SCHEMBL3268358

COc1ccccc1CNc1cc(-c2cccnc2)c2cc(Cl)ccc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 10/20 0.56
CYP3A4 P08684 10/20 0.56
CYP2D6 P10635 10/20 0.56
CYP2C19 P33261 9/20 0.56
CLK4 Q9HAZ1 8/20 0.56
HSD17B10 Q99714 7/20 0.56
USP2 O75604 7/20 0.56
TSHR P16473 6/20 0.56
ALOX15 P16050 4/20 0.56
ALDH1A1 P00352 4/20 0.56
LMNA P02545 4/20 0.56
CYP2C9 P11712 3/20 0.56
MAPK1 P28482 2/20 0.56
TP53 P04637 2/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
KDM4E B2RXH2 2/20 0.53
HPGD P15428 1/20 0.53
HIF1A Q16665 1/20 0.53
PDE5A O76074 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3267078 0.91 ALDH1A1 (0.53) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL3268678 0.85 CYP1A2 (0.52) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL3268428 0.82 CYP1A2 (0.51) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL3267284 0.79 EGFR (0.48) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL3268661 0.79 NPSR1 (0.54) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL8509984 0.75 KCNH2 (0.49) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL3267325 0.75 CYP3A4 (0.49) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL3267094 0.75 CYP1A2 (0.47) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL3267862 0.74 NPSR1 (0.48) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL14474914 0.72 ALDH1A1 (0.59) CYP1A2CYP3A4CYP2D6CYP2C19CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399674-B2 Quinolines HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-20120136018-A1 QUINOLINES KOLCZEWSKI SABINE (DE) 2012-05-31 US disclosed
EP-2195296-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-06-16 EP disclosed
US-20090088451-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 US disclosed
WO-2009040290-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088451-A1 QUINOLINES HTR5A, HTR1A, HTR1E CYP1A2 161/4885CYP3A4 329/4885CYP2D6 250/4885
US-20120136018-A1 QUINOLINES HTR5A, HTR1A, HTR1E CYP1A2 161/4885CYP3A4 329/4885CYP2D6 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.